30508-27-1
30508-27-1 結(jié)構(gòu)式
基本信息
Licorisoflavan B
LICORICIDIN (LCD)
7-O-Demethyllicorisoflavan A
1,3-Benzenediol,4-[(3R)-3,4-dihydro-7-hydroxy-5-methoxy-6-(3-methyl-2-buten-1-yl)-2H-1-benzopyran-3-yl]-2-(3-methyl-2-buten-1-yl)-
物理化學(xué)性質(zhì)
vitamins, nutraceuticals, and natural products
常見問題列表
Licoricidin (LCD) (0-20 μM; 24 hours) dose-dependently inhibits the viability of colon cancer cell lines with various pathological and genetic characters, namely SW480, HCT116, SW620 and LoVo cells, with IC 50 values of 7.2, 5.4, 4.5 and 5.1 μM, respectively. Licoricidin (LCD) (0-20 μM; 0-12 hours) induces cell apoptosis was accompanied with the activation of caspase-3 by cleavage in a time- and dose-dependent manner. Licoricidin (LCD) (0-20 μM; 0-12 hours) induces autophagy of SW480 cells, increases the cleavage of LC3-I to LC3-II and the degradation of p62 in a time and dose dependent manner. Licoricidin (LCD) (0-5 μg/ml; 18 hours) inhibits cell migration, MMP-9 secretion, and VCAM expression in 4T1 cells.
Cell Viability Assay
| Cell Line: | SW480, HCT116, SW620 and LoVo cells |
| Concentration: | 0-20 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased colon cancer cell lines viability. |
Western Blot Analysis
| Cell Line: | SW480 cells |
| Concentration: | 0 μM, 2.5 μM, 5 μM, 10 μM, 20 μM |
| Incubation Time: | 0 hours, 1 hour, 3 hours, 6 hours, 12 hours |
| Result: | Induced cell apoptosis. |
Licoricidin (LCD) (intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 15 days) significantly inhibited the growth of SW480 xenografts in nude mice with an inhibitory rate of 43.5%. Licoricidin (LCD) (intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 32 days) reduces pulmonary metastasis and the expression of CD45, CD31, HIF-1α, iNOS, COX-2, and VEGF-A in tumor tissues, additionally, decreases protein expression of VEGF-R2, VEGF-C, VEGF-R3, and LYVE-1 in tumor tissues of licoricidin-treated mice.
| Animal Model: | SW480 xenografted tumor growth in nude mice |
| Dosage: | 5, 10, or 20 mg/kg |
| Administration: | Intraperitoneal injection; once daily; 15 days |
| Result: | Decreased tumor volumes. |
| Animal Model: | BALB/c mouse orthotopic model |
| Dosage: | 5, 10, or 20 mg/kg |
| Administration: | Intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 32 days |
| Result: | Inhibited Lung Metastasis of 4T1 Murine Mammary Carcinoma cells. |